Therapeutic Solutions International’s Sub, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer
April 12 2017 - 9:31AM
InvestorsHub NewsWire
OCEANSIDE, CA -- April 12, 2017 --
InvestorsHub NewsWire -- Therapeutics Solutions
International, Inc., (OTC PINK: TSOI)
announced today the filing of an Investigational New Drug (IND)
application by
its majority owned subsidiary, Emvolio, Inc.,
for use of its StemVacs cancer immunotherapeutic in patients with
solid tumors. The trial seeks to establish safety and immune
response of the cancer, targeting a new personalized dendritic cell
vaccine.
“Completion of preclinical studies and submission to the
FDA to initiate clinical trials is a major milestone for
Emvolio. We are excited about the prospects of eventually
adding this new weapon in the fight against cancer to the
armamentarium available to oncologists,” said Timothy Dixon,
Chairman of Emvolio. “The fact that StemVacs utilizes cells derived
from the patient being treated, we believe this will provide a
personalized element to this immunotherapy, which we anticipate
will increase the possibility of an effective outcome.”
StemVacs is generated using dendritic cell progenitors isolated
from patients, which are activated by a proprietary process which
has previously been demonstrated to endow dendritic cells with the
ability to produce “natural cytokines”, which kill cancer
cells.
“It is a pleasure to work with the team at Emvolio on clinical
translation of this exciting immunotherapeutic approach to cancer,”
said Boris Reznik, Chairman and CEO of Biorasi, Inc. “As a Contract
Research Organization (CRO) that loves to assist promising
companies operating in the area of the Cutting Edge of Medicine, we
are pleased that our collaboration has culminated into this
regulatory filing.”
Biorasi is a customer-focused Contract Research Organization
(CRO) that optimizes the design and delivery of clinical trials for
its sponsors. Pharmaceutical companies around the globe have come
to depend on Biorasi to consistently deliver success in
clinical-phase development programs. Biorasi's expertise
includes a wide range of molecule types, therapeutic areas, and
regulatory pathways.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
About Emvolio, Inc.
The Company's corporate website is www.emvolio.com. Emvolio,
Inc. is a Delaware corporation.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
Contact Information
Therapeutic Solutions International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024